Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial.
Author
McGregor, GordonSandhu, Harbinder
Bruce, Julie
Sheehan, Bartholomew
McWilliams, David
Yeung, Joyce
Jones, Christina
Lara, Beatriz
Alleyne, Sharisse
Smith, Jessica
Lall, Ranjit
Ji, Chen
Ratna, Mariam
Ennis, Stuart
Heine, Peter
Patel, Shilpa
Abraham, Charles
Mason, James
Nwankwo, Henry
Nichols, Vivien
Seers, Kate
Underwood, Martin
Publication date
2024-02-07
Metadata
Show full item recordAbstract
Objective: To evaluate whether a structured online supervised group physical and mental health rehabilitation programme can improve health related quality of life compared with usual care in adults with post-covid-19 condition (long covid). Design: Pragmatic, multicentre, parallel group, superiority randomised controlled trial. Setting: England and Wales, with home based interventions delivered remotely online from a single trial hub. Participants: 585 adults (26-86 years) discharged from NHS hospitals at least three months previously after covid-19 and with ongoing physical and/or mental health sequelae (post-covid-19 condition), randomised (1:1.03) to receive the Rehabilitation Exercise and psycholoGical support After covid-19 InfectioN (REGAIN) intervention (n=298) or usual care (n=287). Interventions: Best practice usual care was a single online session of advice and support with a trained practitioner. The REGAIN intervention was delivered online over eight weeks and consisted of weekly home based, live, supervised, group exercise and psychological support sessions. Main outcome measures: The primary outcome was health related quality of life using the patient reported outcomes measurement information system (PROMIS) preference (PROPr) score at three months. Secondary outcomes, measured at three, six, and 12 months, included PROMIS subscores (depression, fatigue, sleep disturbance, pain interference, physical function, social roles/activities, and cognitive function), severity of post-traumatic stress disorder, general health, and adverse events. Results: Between January 2021 and July 2022, 39 697 people were invited to take part in the study and 725 were contacted and eligible. 585 participants were randomised. Mean age was 56 (standard deviation (SD) 12) years, 52% were female participants, mean health related quality of life PROMIS-PROPr score was 0.20 (SD 0.17), and mean time from hospital discharge was 323 (SD 144) days. Compared with usual care, the REGAIN intervention led to improvements in health related quality of life (adjusted mean difference in PROPr score 0.03 (95% confidence interval 0.01 to 0.05), P=0.02) at three months, driven predominantly by greater improvements in the PROMIS subscores for depression (1.39 (0.06 to 2.71), P=0.04), fatigue (2.50 (1.19 to 3.81), P<0.001), and pain interference (1.80 (0.50 to 3.11), P=0.01). Effects were sustained at 12 months (0.03 (0.01 to 0.06), P=0.02). Of 21 serious adverse events, only one was possibly related to the REGAIN intervention. In the intervention group, 141 (47%) participants fully adhered to the programme, 117 (39%) partially adhered, and 40 (13%) did not receive the intervention. Conclusions: In adults with post-covid-19 condition, an online, home based, supervised, group physical and mental health rehabilitation programme was clinically effective at improving health related quality of life at three and 12 months compared with usual care.Citation
McGregor G, Sandhu H, Bruce J, Sheehan B, McWilliams D, Yeung J, Jones C, Lara B, Alleyne S, Smith J, Lall R, Ji C, Ratna M, Ennis S, Heine P, Patel S, Abraham C, Mason J, Nwankwo H, Nichols V, Seers K, Underwood M. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial. BMJ. 2024 Feb 7;384:e076506. doi: 10.1136/bmj-2023-076506.Type
ArticleAdditional Links
https://pubmed.ncbi.nlm.nih.gov/38325873/PMID
38325873Journal
BMJPublisher
BMJ Publishing Groupae974a485f413a2113503eed53cd6c53
10.1136/bmj-2023-076506